We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis (NVS) Posts Positive Data From Prostate Cancer Study
Read MoreHide Full Article
Novartis AG (NVS - Free Report) announced the first interpretable data from a late-stage study evaluating the efficacy and safety of its radioligand therapy, 177Lu-PSMA-617, for treating patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
The phase III VISION study met both primary endpoints of overall survival and radiographic progression-free survival in the given patient population. The safety profile of the candidate was similar to data reported in previous studies.
Shares of Novartis have declined 8.7% so far this year compared with the industry’s decrease of 0.2%.
With this positive result, 177Lu-PSMA-617 is inching closer to becoming the targeted treatment option for more than 80% of patients with advanced prostate cancer. Regulatory filing for 177Lu-PSMA-617 in the United States and in the EU are expected to be submitted later in 2021.
Per the press release, Novartis is the only company pursuing four different cancer treatment platforms– radioligand therapy, cell and gene therapy, targeted therapy, and immunotherapy. The company remains focused on reimagining prostate cancer through targeted radioligand therapy with 177Lu-PSMA-617.
Novartis acquired Endocyte to expand expertise in radiopharmaceuticals and transformational therapeutic platforms.
Notably, 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic that targets prostate-specific membrane antigen, or PSMA. Successful development of this candidate will broaden its already strong oncology portfolio.
We note that Novartis has a strong oncology portfolio and continues to work on developing its immuno-oncology pipeline.
Johnson & Johnson’s earnings estimates have been revised 6.6% upward for 2021 and 4.9% for 2022 over the past 60 days. The stock has inched up 1.8% year to date.
Zoetis’ earnings estimates have been revised 4.8% upward for 2021 and 4.2% for 2022 over the past 60 days.
Repligen’searnings estimates have been revised 15.1% upward for 2021 and 9.8% for 2022 over the past 60 days.The stock has increased 7.8% year to date.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Novartis (NVS) Posts Positive Data From Prostate Cancer Study
Novartis AG (NVS - Free Report) announced the first interpretable data from a late-stage study evaluating the efficacy and safety of its radioligand therapy, 177Lu-PSMA-617, for treating patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
The phase III VISION study met both primary endpoints of overall survival and radiographic progression-free survival in the given patient population. The safety profile of the candidate was similar to data reported in previous studies.
Shares of Novartis have declined 8.7% so far this year compared with the industry’s decrease of 0.2%.
With this positive result, 177Lu-PSMA-617 is inching closer to becoming the targeted treatment option for more than 80% of patients with advanced prostate cancer. Regulatory filing for 177Lu-PSMA-617 in the United States and in the EU are expected to be submitted later in 2021.
Per the press release, Novartis is the only company pursuing four different cancer treatment platforms– radioligand therapy, cell and gene therapy, targeted therapy, and immunotherapy. The company remains focused on reimagining prostate cancer through targeted radioligand therapy with 177Lu-PSMA-617.
Novartis acquired Endocyte to expand expertise in radiopharmaceuticals and transformational therapeutic platforms.
Notably, 177Lu-PSMA-617 is a first-in-class radioligand and therapeutic that targets prostate-specific membrane antigen, or PSMA. Successful development of this candidate will broaden its already strong oncology portfolio.
We note that Novartis has a strong oncology portfolio and continues to work on developing its immuno-oncology pipeline.
Zacks Rank & Stocks to Consider
Novartis currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Johnson & Johnson (JNJ - Free Report) , Zoetis Inc. (ZTS - Free Report) and Repligen Corporation (RGEN - Free Report) , all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Johnson & Johnson’s earnings estimates have been revised 6.6% upward for 2021 and 4.9% for 2022 over the past 60 days. The stock has inched up 1.8% year to date.
Zoetis’ earnings estimates have been revised 4.8% upward for 2021 and 4.2% for 2022 over the past 60 days.
Repligen’searnings estimates have been revised 15.1% upward for 2021 and 9.8% for 2022 over the past 60 days.The stock has increased 7.8% year to date.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>